PointState Capital’s Altimmune ALT Stock Holding History

PointState Capital’s Portfolio ALT Stock Details ALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-135,000	Closed	-$1.24M	–	69
2021 Q4	$1.24M	Buy	135,000 +75,000	+125%	+$797K	0.02%	110
2021 Q3	$679K	Sell	60,000 -40,000	-40%	-$486K	0.01%	135
2021 Q2	$985K	Buy	+100,000	New	+$1.37M	0.02%	120
2021 Q1	–	Sell	-50,000	Closed	-$564K	–	119
2020 Q4	$564K	Buy	+50,000	New	+$589K	0.01%	124

Other funds holding ALT

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

AAP

Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

PointState Capital's ALT Position: Q1 2022 in Review

PointState Capital sold out of Altimmune (ALT) in Q1 2022, closing a stake of 135,000 shares — an estimated $1.24M sold.

PointState Capital first reported a position in ALT in Q4 2020 and held it in 4 quarters. The position peaked at $1.24M in Q4 2021. 103 funds tracked by Wall St. Rank hold ALT as of Q1 2022.

PointState Capital reported no remaining Altimmune position as of Q1 2022 after selling out during the quarter.
PointState Capital sold 135,000 Altimmune shares in Q1 2022, an estimated $1.24M.
PointState Capital first reported a position in Altimmune in Q4 2020 and held it in 4 quarters.
PointState Capital's Altimmune position peaked at $1.24M in Q4 2021.
103 funds tracked by Wall St. Rank held Altimmune as of Q1 2022.

Based on PointState Capital's 13F filing for Q1 2022, filed 13 May 2022.